## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application: Listing of Claims

- 1-5. (Canceled).
- 6. (Currently amended) The TFA salt of a compound which is

selected from:

1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]metanamine;

 $1-\{1-[4-(3-phenylbenzo[g]quinoxalin-2-yl)benzyl]piperidin-4-yl\}-1, 3-dihydro-2H-benzimidazol-2-one;$ 

N-{(3R)-1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]pyrrolidin-3-yl}-1,3-thiazole-5-carboxamide;

tert-butyl 1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]azetidin-3-ylcarbamate;

9-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-9H-purin-6-amine;

6-(4-{[4-(3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]methyl}phenyl)-7-phenyl-1H-imidazo[4,5-g]quinoxaline;

or a stereoisomer thereof.

## 7. (Currently amended) A compound which is selected from:

1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]metanamine;

1-{1-[4-(3-phenylbenzo[g]quinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N-{(3R)-1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]pyrrolidin-3-yl}-1,3-thiazole-5-earboxamide;

tert-butyl-1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]azetidin-3-ylcarbamate;

9-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-9H-purin-6-amine;

6-(4-{[4-(3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]methyl}phenyl) 7-phenyl-1H-imidazo[4,5-b]quinoxaline;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

- 8. (Canceled).
- 9. (Original) A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 7.

10-12. (Canceled).

13. (Previously presented) A method for treating ovarian, breast and prostate cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 7.

14-23. (Canceled)

## 24. (New) A compound of the Formula A:

$$(R^{1})_{n} \xrightarrow{V}^{u} X$$

$$A \qquad (R^{2})_{p}$$

$$(R^{2})_{p}$$

wherein:

n is 0, 1 or 2; p is 0, 1, 2 or 3;

is selected from:

R1 is independently selected from:

- 1) OH,
- 2) OC<sub>1</sub>-C<sub>6</sub> alkyl, and
- 3) C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>2</sup> is independently selected from:

- 1) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 2) OH,
- 3) OC<sub>1</sub>-C<sub>6</sub> alkyl,
- 4) CF<sub>3</sub>,
- 5) CN, and
- 6) halogen;

R<sup>3</sup> and R<sup>4</sup> are: H;

 $R^5$  and  $R^6$  are independently selected from: H and  $C_1\text{-}C_6$  alkyl; or

R<sup>5</sup> and R<sup>6</sup> can be taken together with the nitrogen to which they are attached to form:

optionally substituted with Q;

Q is selected from:

or a pharmaceutically acceptable salt or a stereoisomer thereof.